The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2015

Filed:

Feb. 28, 2011
Applicants:

Mark E. Layton, Harleysville, PA (US);

Michael J. Kelly, Wayne, PA (US);

Timothy J. Hartingh, Blue Bell, PA (US);

Inventors:

Mark E. Layton, Harleysville, PA (US);

Michael J. Kelly, Wayne, PA (US);

Timothy J. Hartingh, Blue Bell, PA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 285/14 (2006.01); C07D 417/14 (2006.01); C07D 491/107 (2006.01); C07D 513/04 (2006.01); C07D 471/10 (2006.01); C07D 417/10 (2006.01); C07D 491/113 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01); C07D 498/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 285/14 (2013.01); C07D 417/04 (2013.01); C07D 417/10 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/10 (2013.01); C07D 491/107 (2013.01); C07D 491/113 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention is directed to 5-substituted 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide and 1,3-dihydro[1,2,5]thiadiazolo[3,4-b]pyridine 2,2,-dioxide derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.


Find Patent Forward Citations

Loading…